Featured Tickers:
Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in HUTCHMED (China) Limited or Ligand Pharmaceuticals Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how HUTCHMED (China) Limited and Ligand Pharmaceuticals Incorporated compare based on key financial metrics to determine which better meets your investment needs.
About HUTCHMED (China) Limited and Ligand Pharmaceuticals Incorporated
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton’s tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
Latest Pharmaceuticals and HUTCHMED (China) Limited, Ligand Pharmaceuticals Incorporated Stock News
As of March 6, 2025, HUTCHMED (China) Limited had a $2.7 billion market capitalization, compared to the Pharmaceuticals median of $203.6 million. HUTCHMED (China) Limited’s stock is up 14.9% in 2025, up 0.5% in the previous five trading days and up 5.95% in the past year.
Currently, HUTCHMED (China) Limited does not have a price-earnings ratio. HUTCHMED (China) Limited’s trailing 12-month revenue is $610.8 million with a -6.9% net profit margin. Year-over-year quarterly sales growth most recently was -42.6%. Analysts expect adjusted earnings to reach $-0.157 per share for the current fiscal year. HUTCHMED (China) Limited does not currently pay a dividend.
As of March 6, 2025, Ligand Pharmaceuticals Incorporated had a $2.2 billion market cap, putting it in the 60th percentile of all stocks. Ligand Pharmaceuticals Incorporated’s stock is up 7.1% in 2025, down 6.1% in the previous five trading days and up 52.07% in the past year.
Currently, Ligand Pharmaceuticals Incorporated does not have a price-earnings ratio. Ligand Pharmaceuticals Incorporated’s trailing 12-month revenue is $167.1 million with a -2.4% net profit margin. Year-over-year quarterly sales growth most recently was 52.3%. Analysts expect adjusted earnings to reach $6.098 per share for the current fiscal year. Ligand Pharmaceuticals Incorporated does not currently pay a dividend.
How We Compare HUTCHMED (China) Limited and Ligand Pharmaceuticals Incorporated Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at HUTCHMED (China) Limited and Ligand Pharmaceuticals Incorporated’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions